Page last updated: 2024-10-22
ambroxol and Infections, Paramyxoviridae
ambroxol has been researched along with Infections, Paramyxoviridae in 1 studies
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "It was investigated whether the botanical drug combination Sinupret is able to modulate the resistance of mice to a respiratory tract infection with Sendai virus (Parainfluenza viridae) if given prophylactically to the animals." | 1.31 | Enhanced resistance to Sendai virus infection in DBA/2J mice with a botanical drug combination (Sinupret). ( März, RW; Ottendorfer, D; Schmolz, M; Sieder, C, 2001) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Schmolz, M | 1 |
| Ottendorfer, D | 1 |
| März, RW | 1 |
| Sieder, C | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Herbal Formula (SBL) for the Treatment of Perennial Allergic Rhinitis: A Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT00456755] | Phase 2 | 126 participants (Actual) | Interventional | 2004-03-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4
The severity of PAR was evaluated by means of a daily symptom diary chart. Patients were instructed to grade retrospectively everyday before bedtime, their generalwell-being, nasalsymptoms (nasal blockage, rhinorrhea, nose itching, sneezing) and non-nasal symptoms(itching eyes, tearing eyes, redness of eyes, itching of ears or palate) on the diary chart. A 4-point severity scale from no symptoms (0), mild (1), moderated (2) to severe (3) was used. (NCT00456755)
Timeframe: 4 week
| Intervention | Unit Score (Mean) |
|---|
| General Health | Nose Blockage | Rhinorrhea volume | Sneeze Frequency | Nose Itching | Eyes Itching | Tears | Eye Congestion | Ear itching |
|---|
| Placebo | 2.8 | 1.21 | 1.24 | 1.18 | 0.99 | 0.56 | 0.43 | 0.26 | 0.61 |
,| Shi-Bi-Lin | 2.82 | 1.19 | 1.26 | 1.15 | 1.11 | 0.73 | 0.52 | 0.37 | 0.81 |
Quality of Life (Difference Between Baseline and Week 4)
SF-36 QOL questionnaire administrated before and after treatment. It has eight domains: general health (GH), physical functioning (PF), social functioning (SF), role limitation caused by physical problems (RP), bodily pain (BP), role limitations caused by emotional problem (RE), mental health (MH), and vitality (VT). Each domain was started from 0 (worst health) to 100 (best health). (NCT00456755)
Timeframe: 4 week
| Intervention | Unit Score (Mean) |
|---|
| Physical functioning | Role limitation by physical problem | Bodily pain | General Health | Vitality | Socail functioning | Role limitation by emotional problem | Mental health |
|---|
| Placebo | 0 | 3 | -10 | -9 | 13 | 17 | 3 | 1 |
,| Shi-Bi-Lin | 4 | 7 | -3 | -7 | 8 | 17 | 13 | 1 |
Other Studies
1 other study available for ambroxol and Infections, Paramyxoviridae